Rebuffet, Lucas http://orcid.org/0009-0009-0641-3942
Melsen, Janine E. http://orcid.org/0000-0001-5322-7194
Escalière, Bertrand
Basurto-Lozada, Daniela http://orcid.org/0000-0003-3943-8424
Bhandoola, Avinash http://orcid.org/0000-0002-4657-8372
Björkström, Niklas K.
Bryceson, Yenan T. http://orcid.org/0000-0002-7783-9934
Castriconi, Roberta http://orcid.org/0000-0003-2806-1115
Cichocki, Frank http://orcid.org/0000-0003-3043-0653
Colonna, Marco http://orcid.org/0000-0001-5222-4987
Davis, Daniel M. http://orcid.org/0000-0002-9182-291X
Diefenbach, Andreas http://orcid.org/0000-0002-9176-9530
Ding, Yi
Haniffa, Muzlifah http://orcid.org/0000-0002-3927-2084
Horowitz, Amir
Lanier, Lewis L. http://orcid.org/0000-0003-1308-3952
Malmberg, Karl-Johan http://orcid.org/0000-0002-8718-9373
Miller, Jeffrey S. http://orcid.org/0000-0002-0339-4944
Moretta, Lorenzo http://orcid.org/0000-0003-4658-1747
Narni-Mancinelli, Emilie http://orcid.org/0000-0002-7001-1026
O’Neill, Luke A. J.
Romagnani, Chiara http://orcid.org/0000-0002-5167-7463
Ryan, Dylan G.
Sivori, Simona
Sun, Dan http://orcid.org/0000-0003-2147-9308
Vagne, Constance
Vivier, Eric http://orcid.org/0000-0001-7022-8287
Article History
Received: 16 January 2024
Accepted: 23 May 2024
First Online: 2 July 2024
Competing interests
: E.V. and C.V. are employees of Innate Pharma. K.-J.M. is a consultant at Fate Therapeutics and Vycellix and receives research support from Fate Therapeutics, Oncopeptides for studies unrelated to this work. The other authors declare no competing interests.